checkAd
    Startseite > Aktien > ImmunityBio > Nachrichten
    ImmunityBio Aktie
    8,1200
     
    USD
    +0,74 %
    +0,0600 USD
    Letzter Kurs 11.05.24 Nasdaq
    8,1000
     
    USD
    1.300 STK
    Geldkurs 10.05.24
    8,1200
     
    USD
    200 STK
    Briefkurs 10.05.24
    ISIN: US45256X1037 · WKN: A2QQ2E · SYM: IBRX · USA

    Neueste Nachrichten

    ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA
    07.05.24 · Business Wire (engl.) · ImmunityBio
    ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
    02.05.24 · Business Wire (engl.) · ImmunityBio
    ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association
    30.04.24 · Business Wire (engl.) · ImmunityBio
    ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
    25.04.24 · Business Wire (engl.) · ImmunityBio
    Fokus Aktien mit extremen Handelsvolumen am Dienstag, den 23.04.2024
    23.04.24 · wO Chartvergleich · AGROB Immobilien
    ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    23.04.24 · Business Wire (engl.) · ImmunityBio
    Fokus Aktien mit extremen Handelsvolumen am Mittwoch, den 20.03.2024
    20.03.24 · wO Chartvergleich · Avista
    NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
    06.03.24 · Business Wire (engl.) · ImmunityBio
    N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
    05.03.24 · Business Wire (engl.) · ImmunityBio
    ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
    21.02.24 · Business Wire (engl.) · ImmunityBio
    ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
    05.02.24 · Business Wire (engl.) · ImmunityBio
    ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
    16.11.23 · Business Wire (engl.) · ImmunityBio